Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

Background: Poly (ADP-ribose) polymerase (PARP) inhibitor and antiangiogenic agent monotherapy have shown to be effective as maintenance treatment in patients with ovarian cancer (OC). However, there is currently a lack of evidence-based study to directly compare the effects of combination therapy w...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Yan Wei, Li He, Tao Liu, Tao Guo, Cong Xie, Jigang Jia, Yonghong Lin, Jiang Liu, Jiayin Fan
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2024-03-01
Цуврал:	Frontiers in Pharmacology
Нөхцлүүд:	PARP inhibitors antiangiogenic agents olaparib bevacizumab ovarian cancer combination therapy
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1372077/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!